D

    Dyadic International Inc (DYAI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.56
    -0.06 (-9.61%)

    Market Cap: $24.60M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    47%(14/30)
    Avg Surprise
    -41.23%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.04
    Range$-0.06 - $-0.03
    3 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.04+0.0%
    60d ago$-0.03+25.0%
    30d ago$-0.03+25.0%
    7d ago$-0.03+25.0%
    Current$-0.04
    Revenue Consensus
    $1M
    Range$1M - $2M
    2 analysts
    Dec 31, 2026
    EPS Consensus$-0.02
    Range$-0.03 - $-0.01
    2 analysts
    Revenue Consensus
    $3M
    Range$2M - $5M
    3 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.02---
    Sep 26EST
    		-$-0.04---
    Jun 26
    		$-0.06$-0.03-100.00%Miss+0.0%
    Mar 26
    		$-0.05$-0.04-25.00%Miss+26.3%
    Dec 25
    		$-0.04$-0.04-11.03%Miss+13.4%
    Sep 25
    		$-0.06$-0.04-50.00%Miss-500.0%
    Jun 25
    		$-0.06$-0.06+0.00%Beat+14.3%
    Mar 25
    		$-0.07$0.00N/ABeat+2.7%
    Dec 24
    		$-0.05$-0.04-25.00%Miss+37.5%
    Sep 24
    		$-0.01N/A+85.71%Beat+83.3%
    Jun 24
    		$-0.07$-0.06-16.67%Miss+0.0%
    Mar 24
    		$-0.07$-0.07+0.43%Beat-332.3%
    Dec 23
    		$-0.08$-0.06-33.33%Miss-14.3%
    Sep 23
    		$-0.06$-0.06+0.00%Beat+0.0%
    Jun 23
    		$-0.07$-0.05-40.00%Miss+41.7%
    Mar 23
    		$0.03$-0.03+200.00%Beat+133.3%
    Dec 22
    		$-0.07$-0.07+0.00%Beat+53.3%
    Sep 22
    		$-0.06$-0.09+33.33%Beat+0.0%
    Jun 22
    		$-0.12$-0.07-71.43%Miss+14.3%
    Mar 22
    		$-0.09$-0.14+35.71%Beat+25.0%
    Dec 21
    		$-0.15$-0.02-650.00%Miss-114.3%
    Sep 21
    		$-0.06$-0.10+40.00%Beat+33.3%
    Jun 21
    		$-0.14$-0.09-55.56%Miss-40.0%
    Mar 21
    		$-0.12$0.09-233.33%Miss-50.0%
    Dec 20
    		$-0.07$-0.08+12.50%Beat+0.0%
    Sep 20
    		$-0.09$-0.07-28.57%Miss-50.0%
    Jun 20
    		$-0.10$-0.07-42.86%Miss+0.0%
    Mar 20
    		$-0.08$-0.02-300.00%Miss+0.0%
    Dec 19
    		$-0.07$-0.07+0.00%Beat-250.0%
    Sep 19
    		$-0.06$-0.07+14.29%Beat+0.0%
    Jun 19
    		$-0.10$-0.07-42.86%Miss-66.7%
    Mar 19
    		$-0.08$0.00N/ABeat-14.3%
    Dec 18
    		$-0.02N/A+66.67%Beat+0.0%
    Sep 18
    		$-0.06$-0.06+0.00%Beat-20.0%
    Jun 18
    		$-0.06N/AN/ABeat-20.0%
    Mar 18
    		$-0.07N/AN/ABeat-200.0%
    Dec 17
    		$-0.02N/AN/ABeat+66.7%
    Sep 17
    		$-0.05N/AN/ABeat-55.3%
    Jun 17
    		$-0.05N/AN/ABeat-
    Mar 17
    		$0.07N/AN/ABeat-
    Dec 16
    		$-0.06N/AN/ABeat-
    Sep 16
    		$-0.03N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-2.60EV/EBITDA-2.93x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-200.50%Operating Margin-212.80%
    ROE-2827.00%ROIC231.89%
    Financial Health
    Debt/Equity-0.00xInterest Coverage-16.69x
    Current Ratio1.65xQuick Ratio1.65x
    Trading Statistics
    Beta1.02Avg Volume179.77K
    52-Week High$1.6052-Week Low$0.60

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.67
    SMA 20$0.80
    SMA 50$0.95
    SMA 200$0.87
    EMA 10$0.68
    EMA 20$0.77
    EMA 50$0.87
    EMA 200$0.90

    MACD

    Line: -0.11Signal: -0.09Hist: -0.02

    ADX

    ADX: 29.1+DI: 11.2-DI: 28.4

    Aroon & PSAR

    Aroon Up4.0
    Aroon Down100.0
    PSAR$0.69

    Bollinger Bands

    Upper Band$1.13
    Lower Band$0.48
    %B Position8068%(Upper)
    Band Width0.12

    RSI (14-Day)

    Oversold
    25.0

    Momentum Oscillators

    Stoch %K5.1
    Stoch %D3.9
    Williams %R-91.6
    ROC (10d)-28.9%
    Momentum-0.23
    CCI (20d)-117.2
    MFI (14d)2.1

    Volatility Measures

    ATR (14d)$0.09(16.6%)
    StdDev (20d)0.16
    Hist Vol88.7%(High)

    Volume Flow

    VWAP$0.57
    OBV-13.1M
    AD Line-11.5M
    CMF (20d)-0.451

    Volume Metrics

    Avg Vol (20d)186.1K
    Vol Ratio1.4x
    VWMA (20d)$0.81

    Pivot Points

    R3$0.71
    R2$0.69
    R1$0.65
    Pivot Point$0.63
    S1$0.59
    S2$0.56
    S3$0.53

    Advanced Oscillators

    TSI-34.94
    Ultimate Osc23.1
    KST-340.28

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$961,138$1.11M$235,716$1.16M$463,449$183,100$817,376$1.96M$385,896$334,617$686,535$397,060
    Cost of Revenue$984,165$791,840$384,608$254,753$613,591$297,658$352,819$395,894$301,956$143,955$350,118$105,869
    Gross Profit$-23,027$319,116$-148,892$909,864$-150,142$-114,558$464,557$1.56M$83,940$190,662$336,417$291,191
    Operating Expenses$2.03M$2.23M$1.38M$2.84M$1.58M$1.89M$1.99M$1.76M$2.13M$2.32M$2.50M$2.01M
    R&D$332,621$476,069$458,436$350,046$629,379$494,979$545,660$460,241$515,629$522,723$852,797$716,351
    SG&A$1.69M$1.76M$1.25M$1.48M$1.44M$1.60M$1.44M$1.30M$1.61M$1.79M$1.65M$1.28M
    Operating Income$-2,054,204$-1,912,284$-1,524,929$-1,925,369$-1,729,068$-2,002,475$-1,530,059$-202,614$-2,042,591$-2,125,558$-2,168,420$-1,720,121
    Interest Income$0$57,191$83,033$63,467$49,127$88,458$103,747$127,331$138,471$87,443$96,899$105,862
    Interest Expense$109,385$109,181$114,392$85,934$113,833$113,562$126,233$128,177$141,103$32,458$1.09M$0
    Income Before Tax$-2,123,884$-1,954,683$-1,567,263$-1,976,012$-1,793,774$-2,027,579$-1,550,880$-203,460$-2,045,223$-2,009,596$-4,240,222$-1,614,259
    Income Tax Expense$0$0$0$0$0$0$43,277$0$-2,039,445$-43,277$-2,168,424$-118,462
    Net Income$-2,123,884$-1,954,683$-1,567,263$-1,976,012$-1,793,774$-2,027,579$-1,550,880$-203,460$-2,045,223$-2,009,596$-2,071,797$-1,614,259
    EBITDA$-2,014,499$-1,845,502$-1,434,529$-1,890,078$-1,679,941$-1,902,255$-1,420,073$-75,288$-1,904,120$-1,977,138$-811,857$-1,614,259
    EBITN/AN/A$-1,452,871N/AN/A$-1,914,017$-1,424,645$-202,614$-1,904,120$-1,038,501$-2,980,280$-3,402,442
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about DYAI

    News

    Llamada de resultados del T2 de 2026 de Dyadic International (DYAI): progreso comercial y riesgo de liquidez

    Dyadic International (DYAI) reportó ingresos estables en el segundo trimestre de 2026 de $961,000, con una pérdida neta que aumentó a $2.1 millones, y sus ingresos del primer semestre crecieron un 52% a $2.1 millones. A pesar de los progresos comerciales, la empresa finalizó el trimestre con $4.8 millones en efectivo, lo que plantea dudas sobre su capacidad para continuar como empresa en funcionamiento bajo la norma ASC 205-3. Dyadic está impulsando un modelo de negocio con envíos de productos y alianzas estratégicas, buscando capital adicional no dilutivo para mitigar los riesgos de liquidez y financiar su expansión operativa a largo plazo.

    TradingKey•8/14/26•
    Neutral

    Dyadic International, Inc. Secures $2.9 Million Through Registered Direct Offering and Concurrent Private Placement

    Dyadic International, Inc. announced it has secured approximately $2.9 million through definitive agreements with an institutional investor. This funding comes from a registered direct offering of Common Stock and a concurrent private placement of warrants. The proceeds will be used for general corporate purposes and working capital.

    GlobeNewswire•8/13/26•
    Bullish

    Dyadic Expands Commercial Non-Animal Dairy Pipeline Through New Strategic Development Agreement

    Dyadic International, Inc. announced an expanded commercial non-animal dairy pipeline through a new development and commercial license agreement with a European biotechnology company for additional precision-fermented dairy proteins. This agreement enhances Dyadic's food and nutrition portfolio and reinforces its strategy of recurring revenue through strategic partnerships. The company's Dapibus™ precision fermentation platform enables the rapid and efficient development of commercially relevant dairy proteins and enzymes for various food and nutrition markets.

    GlobeNewswire•8/5/26•
    Bullish

    Dyadic International, Inc.: Dyadic Expands Commercial Non-Animal Dairy Pipeline Through New Strategic Development Agreement

    Dyadic International, Inc. announced a new development and commercial license agreement with a European biotechnology company to expand its non-animal dairy pipeline. This agreement leverages Dyadic's Dapibus precision fermentation platform for commercially relevant dairy proteins and enzymes, aiming to generate recurring revenue through strategic partnerships and licensing. The initiative supports the growing demand for sustainable, high-quality animal-free dairy ingredients for various food and nutrition applications.

    FinanzNachrichten.de•8/4/26•
    Bullish

    Dyadic to Report Q2 2026 Financial Results and Host Conference Call on Wednesday August 12, 2026

    Dyadic International, Inc. (Nasdaq: DYAI) announced it will report its financial results for the quarter ended June 30, 2026, and host a conference call on Wednesday, August 12, 2026, at 5:00 p.m. Eastern Time. The call will provide a corporate update, and details for dial-in and webcast access have been provided. The company also highlighted its proprietary gene expression platforms for producing high-value proteins in various life science and industrial applications.

    GlobeNewswire•8/3/26•
    Neutral

    Frequently Asked Questions About DYAI

    Does DYAI pay dividends?
    Dyadic International Inc (DYAI) does not currently pay a regular dividend.
    What is DYAI's market cap?
    Dyadic International Inc (DYAI) has a market capitalization of $24.60M with a current stock price of $0.56.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In